Benitec Biopharma Ltd Stock Alpha and Beta Analysis
| BNTC Stock | USD 13.47 0.46 3.30% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Benitec Biopharma Ltd. It also helps investors analyze the systematic and unsystematic risks associated with investing in Benitec Biopharma over a specified time horizon. Remember, high Benitec Biopharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Benitec Biopharma's market risk premium analysis include:
Beta 1.4 | Alpha 0.0426 | Risk 4.72 | Sharpe Ratio 0.016 | Expected Return 0.0756 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Benitec Biopharma Backtesting, Benitec Biopharma Valuation, Benitec Biopharma Correlation, Benitec Biopharma Hype Analysis, Benitec Biopharma Volatility, Benitec Biopharma History and analyze Benitec Biopharma Performance. Benitec Biopharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Benitec Biopharma market risk premium is the additional return an investor will receive from holding Benitec Biopharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Benitec Biopharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Benitec Biopharma's performance over market.| α | 0.04 | β | 1.40 |
Benitec Biopharma expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Benitec Biopharma's Buy-and-hold return. Our buy-and-hold chart shows how Benitec Biopharma performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Benitec Biopharma Market Price Analysis
Market price analysis indicators help investors to evaluate how Benitec Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Benitec Biopharma shares will generate the highest return on investment. By understating and applying Benitec Biopharma stock market price indicators, traders can identify Benitec Biopharma position entry and exit signals to maximize returns.
Benitec Biopharma Return and Market Media
The median price of Benitec Biopharma for the period between Fri, Oct 3, 2025 and Thu, Jan 1, 2026 is 13.53 with a coefficient of variation of 10.39. The daily time series for the period is distributed with a sample standard deviation of 1.44, arithmetic mean of 13.84, and mean deviation of 1.17. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Insider Trading | 11/03/2025 |
2 | Acquisition by Suvretta Capital Management, Llc of 751111 shares of Benitec Biopharma at 13.5 subject to Rule 16b-3 | 11/07/2025 |
3 | Benitec Biopharma sees 20 million investment from Suvretta Capital By Investing.com - Investing.com | 11/10/2025 |
4 | Is Benitec Biopharma Inc. stock affected by interest rate hikes - Long Setup Reliable Intraday Trade Alerts - newser.com | 11/19/2025 |
5 | What is HC Wainwrights Estimate for BNTC Q2 Earnings | 11/25/2025 |
6 | Acquisition by Buchi J Kevin of 35000 shares of Benitec Biopharma at 12.23 subject to Rule 16b-3 | 12/01/2025 |
7 | Benitec Biopharma shareholders approve all proposals at annual meeting - Investing.com | 12/02/2025 |
8 | Benitec Biopharma prices 100M stock offering - MSN | 12/08/2025 |
9 | Is Benitec Biopharma Inc a good long term investment - VWAP Trading Strategies Free Risk Assessment and Control - earlytimes.in | 12/15/2025 |
10 | Acquisition by Suvretta Capital Management, Llc of 2434 shares of Benitec Biopharma at 11.48 subject to Rule 16b-3 | 12/19/2025 |
11 | Acquisition by Suvretta Capital Management, Llc of 2892 shares of Benitec Biopharma at 12.08 subject to Rule 16b-3 | 12/22/2025 |
12 | Acquisition by Suvretta Capital Management, Llc of 7400 shares of Benitec Biopharma at 12.85 subject to Rule 16b-3 | 12/23/2025 |
13 | Does Benitec Biopharma Have the Potential to Rally 83.87 percent as Wall Street Analysts Expect | 12/24/2025 |
14 | Acquisition by Suvretta Capital Management, Llc of 2516 shares of Benitec Biopharma at 13.1 subject to Rule 16b-3 | 12/26/2025 |
15 | Acquisition by Suvretta Capital Management, Llc of 11587 shares of Benitec Biopharma at 13.44 subject to Rule 16b-3 | 12/29/2025 |
About Benitec Biopharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Benitec or other stocks. Alpha measures the amount that position in Benitec Biopharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Dividend Yield | 0.001357 | 0.001206 | Price To Sales Ratio | 310.41 | 273.39 |
Benitec Biopharma Upcoming Company Events
As portrayed in its financial statements, the presentation of Benitec Biopharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Benitec Biopharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Benitec Biopharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Benitec Biopharma. Please utilize our Beneish M Score to check the likelihood of Benitec Biopharma's management manipulating its earnings.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Benitec Biopharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Benitec Biopharma Backtesting, Benitec Biopharma Valuation, Benitec Biopharma Correlation, Benitec Biopharma Hype Analysis, Benitec Biopharma Volatility, Benitec Biopharma History and analyze Benitec Biopharma Performance. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Benitec Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.